Biohaven Ltd. (BHVN)
NYSE NYSE Primary 
Biohaven: Despite Today's Gains, I Remain Skeptical
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs. BHVN - spun out of the original Biohaven after its acquisition by Pfizer - also has degrader assets focused on autoimmune diseases. Furthermore, there is a Parkinson's program and Obesity program, and some notable catalysts are arriving this year, e.g., pivotal epilepsy topline data.
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?
The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial
Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal of a phase 2 trial.
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Opakalim for depression and Taldefgrobep alfa for SMA missed primary endpoints. Current cash runway is approximately 3.1 quarters, heightening urgency for successful near-term clinical milestones and FDA approvals.
Biohaven's depression drug fails mid-stage trial, shares fall
Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year.
Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know
The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know
Biohaven Ltd. (BHVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52%
The average of price targets set by Wall Street analysts indicates a potential upside of 127.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biohaven Insiders Bet $33 Million on a Turnaround
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.
Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict
BHVN's lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with Oberland Capital. Moreover, BHVN's pipeline is diverse, including other neurology, immunology, oncology, and obesity programs.
